The role of increased lipoprotein (a) and apolipoprotein B-100 levels, and their link to cholesterol and triglyceride concentration in coronary heart disease patients

Aim. To investigate lipid profile, lipoprotein (a) [Lp(а)] and apolipoprotein В-100 (apo В-100) levels in coronary heart disease (CHD) patients. To identify significant CHD predictors and their association with cholesterol (CH) and triglyceride (TG) levels. Material and methods. In total, 575 patients (main group), aged 66,56±12,51 years, with verified CHD were included, as well as 86 individuals (control group), aged 55,47±11,47 years, without cardiovascular disease (CVD). Results. Levels of apo B-100 – 128,17 mg/dl (р<0,00001) and Lp(a) – 27,6 mg/dl (р<0,007) were significantly higher in all CHD patients than in control group. Lp(a) level was significantly higher in acute coronary syndrome (ACS) patients, comparing to control group (р<0,02). Increased apo B-100 leve, 130,9±46,5 mg/dl was a significant (р<0,00001) risk factor (RF) for ACS in CHD patients. There was a significant correlation between Lp(a) (р<0,00003) or apo B-100 (р<0,00001) levels and CH or TG concentrations in CHD individuals. Conclusion. Lp(a) and apo B-100 levels were significant RF for CHD (including acute myocardial infarction) development. Maximal concentration of Lp(a) was observed in CHD patients with hypercholesterolemia (HCH); maximal apo B-100 level – in CHD and hypertriglyceridemia participants.

1. Перова Н.В., Щербакова И.А., Нечаев А.С. и др. Показатели атерогенности липопротеидов плазмы крови и коронарный атеросклероз (по данным селективной ангиографии). Кардиология 1985; 10: 91-5.

2. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации Комитета экспертов Всероссийского научного общества кардиологов. Москва 2004; 36 c.

3. Avogaro P, Cazzolato G, Bittolo Bon G, Oninci GB. Are apolipoproteins better discriminators than lipids for atherosclerosis? Lancet 1979; 1: 901-3.

4. Bachorik PS, Lovejoy KL, Carroll MD, Johnson CL. Apolipoprotein B and AI distributions in the United States, 1988– 1991: results of the National Health and Nutrition Examination Survey III (NHANES III). Clin Chem 1997; 43: 2364-78.

5. Barbir M, Wile D, Trayner I, et al. High prevalence of hypertriglyceridaemia and apolipoprotein abnormalities in coronary artery disease. Br Heart J 1988; 60: 397-403.

6. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA 1996; 276: 544-8.

7. Bostom AG, Gagnon DR, Cupples A, et al. A prospective investigation of elevated lipoprotein(a) levels detected by electrophoresis and cardiovascular disease in women. Circulation 1994; 90: 1688-95.

8. Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 2002; 106: 2526-9.

9. Cremer P, Nagel D, Mann H, et al. Ranking of Lp(a) as a cardiovascular risk factor: results from a 10-year prospective study. In: Woodford P.P., Davignon J., Sniderman A. (Ed.), Atherosclerosis X. Elsevier Science 1995: 903-7.

10. De Backer G, Ambrosioni E, Borch-Johnson K, et al. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Eur Heart J 2003; 24: 1601-10.

11. Ezov MV, Afanasieva OI, Adamova L, et al. Lipoprotein(a) levels predict myocardial infarction in yang men. Aterosclerosis 2000; 1(151): 304-5.

12. Hamsten A, Walldius G, Dahlen G, et al. Serum lipoproteins and apolipoproteins in young male survivors of myocardial infarction. Atherosclerosis 1986; 59: 223-35.

13. Hoefler G, Hamoncourt F, Paschke E, et al. Lipoprotein(a): a risk factor for myocardial infarction. Arteriosclerosis 1988; 8: 398-401.

14. Jovicic A, Ivanisevic V, Ivanovic I. Lipoprotein(a) in patients with carotid atherosclerosis and ischemic cerebrovascular disorders. Atherosclerosis 1993; 98: 59-65.

15. Jurgens G, Taddei-Peters WC, Koltringer P, et al. Lipoprotein(a) concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Stroke 1995; 26: 1841-8.

16. Klausen IC, Sjol A, Hansen PS, et al. Apolipoprotein (a) isoforms and coronary heart disease in men. A nested case-control study. Atherosclerosis 1997; 132: 77-84.

17. Kostner GM. Hyperlipoproteinemia of lipoprotein Lp(a). Atherosclerosis and cardiovascular disease, 7th international meeting / Eds. Descovich G.C., Gaddi A., Magri G.L., Lenzi S. -the Netherlands: Kluwer academic publishers 1990; 136-43.

18. Miremadi Saman, Sniderman А, Jiri Frohlich J. Can Measurement of Serum Apolipoprotein B Replace the Lipid Profile Monitoring of Patients with Lipoprotein Disorders? Clin Chem 2002; 48: 484-8.

19. Nguyen TT, Ellefson RD, Hodge DO, et al. Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation 1997; 96: 1390-7.

20. Reardon MF, Nestel PJ, Craig IH, Harper RW. Lipoprotein predictors of the severity of coronary heart disease in men and women. Circulation 1985; 71: 881-8.

21. Ridker PM, Stampfer MJ, Hennekens CH. Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA 1995; 273: 1269-73.

22. Sewdarsen M, Desai RK, Vythilingum S, et al. Serum lipoproteins and apolipoproteins in young normocholesterolaemic, nondiabetic Indian men with myocardial infarction. Postgrad Med J 1991; 67: 159-64.

23. Sigurdsson G, Baldursdottir A, Sigvaldason H, et al. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol 1992; 69: 1251-4.

24. Stubs P, Seedt M, Lanet D, et al. Lipoprotein(a) as a risk predictor for cardiac mortality in patients with acute coronary syndromes. Eur Heart J 1998; 19: 1355-64.

25. Wald NJ, Law M, Watt HC, et al. Apolipoproteins and ischaemic heart disease: implications for screening. Lancet 1994; 343: 75-9.

26. Williams К, Sniderman AD, Naveed Sattar, et al. Comparison of the Associations of Apolipoprotein B and Low-Density Lipoprotein Cholesterol With Other Cardiovascular Risk Factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2003; 108: 2312-3.